| HOME >> BIOLOGY >> TECHNOLOGY |
Avicena currently supplies its patent-protected ingredients to leading manufacturers of dermaceutical and cosmeceutical products. Avicena is also actively researching and developing additional proprietary formulations to complement its current dermaceutical product portfolio.
ABOUT AVICENA
Avicena Group, Inc. is a Palo Alto, California-based late-stage biotechnology company that develops central nervous system therapeutics for neurodegenerative diseases. The company's core technologies, supported by a robust intellectual property portfolio, have broad applications in both pharmaceuticals and dermaceuticals. Avicena's pharmaceutical program centers on rare neurological disorders (orphan diseases). The company is currently analyzing data from its Phase IIb/III trial in ALS. In the near term, Avicena intends to initiate a Phase III trial in Huntington's disease to accompany the ongoing NIH Phase III trial in Parkinson's disease. Avicena's science is well established and its products are safe and well tolerated. Unlike traditional biotechnology companies, Avicena's clinical programs are largely funded by government and non-profit organizations. Avicena presently derives revenue from the sale of proprietary dermaceutical ingredients to skin care manufacturers.
ABOUT RITA Corporation
Over the past 54 years, RITA Corporation has positioned itself as a
leading supplier of specialty chemicals to the personal care industry.
Headquartered in Crystal Lake, Illinois, RITA operates five wholly-owned
distribution centers across the United States and is represented by
international agents on six continents. In addition to exclusive
distributorships with
'/>"/>
| SOURCE Avicena Group, Inc. Copyright©2007 PR Newswire. All rights reserved |